MAP2K7 and non-small cell lung carcinoma: In NSCLC, mechanisms of ERK reactivation mainly involved BRAF variants, BRAF gene amplification or secondary mutations in other genes of the MAPK/ERK signalling pathway such as NRAS/KRAS or MEK mutations, leading to BRAF-independent reactivation of ERK signalling [10].